Updates are available Correction dated 2019-03-14

Article History

Received: 5 July 2018

Accepted: 26 September 2018

First Online: 22 October 2018

Change Date: 14 March 2019

Change Type: Correction

Change Details: .

Ethics approval and consent to participate

: The CheckMate 016 study was approved by the local site-specific institutional review boards or an independent ethics committee and conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines. Written informed consent was obtained from all patients based on Declaration of Helsinki principles before initiation of any study procedures. The trail was registered on(NCT01472081) on November 16, 2011.

: Not applicable.

: The following represents disclosure information provided by authors of this manuscript.<b>AA.</b> Honoraria: Bristol-Myers Squibb, Pfizer, Merck, Exelixis. Consulting or Advisory Role: Bristol-Myers Squibb, Merck. Research Funding: Bristol-Myers Squibb, Merck, Dynavax. Travel, Accommodations, Expenses: Bristol-Myers Squibb, Pfizer, Merck, Exelixis. <b>ERP.</b> Consulting or Advisory Role: Bristol-Myers Squibb, Acceleron, Astellas, AstraZeneca, Dendreon, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Eli Lilly Inc., SynerGene Therapeutics, Inovio, Clovis, Horizon Pharma, Exelixis, Aveo Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), Dendreon (Inst), GlaxoSmithKline (Inst), Eli Lilly Inc. (Inst), Merck (Inst), Peloton (Inst), Pfizer (Inst). Research Funding: Bristol-Myers Squibb, Acceleron (Inst), AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: U.S. Patent Application No. 14/588,503, pending, filed 1/2/2015; US Patent Application No. 15/226,474, pending, filed 7/1/2015. Travel, Accommodations, Expenses: Bristol-Myers Squibb. Other Relationship: Bristol-Myers Squibb (fees for participating in review activities; for writing or reviewing the manuscript; for providing writing assistance, medicines, equipment, or admin support; development of educational presentations); Merck (fees for development of educational presentations); Roche (fees for development of educational presentations); Novartis (fees for development of educational presentations). <b>MSE.</b> Stock ownership (managed account): Bristol-Myers Squibb. <b>LDL.</b> No relationship to disclose. <b>TMB.</b> Employment: Tennessee Oncology, Sarah Cannon Research Institute. Consulting or Advisory Role: Ignyta (Inst), Guardant Health, Loxo, Pfizer, Moderna Therapeutics (Inst). Research Funding: (Inst) Daiichi Sankyo, Medpacto, Inc., Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, Leap Therapeutics, MabVax, Stemline Therapeutics, Merck, Lilly, GlaxoSmithKline, Novartis, Pfizer, Principa Biopharma, Genentech/Roche, Deciphera, Merrimack, Immunogen, Millennium, Ignyta, Calithera Biosciences, Kolltan Pharmaceuticals, Peleton, Immunocore, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Moderna Therapeutics, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio. <b>DFM.</b> Consulting or Advisory Role: Array BioPharma, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Merck, Novartis, Pfizer. Research Funding: Prometheus (Inst). <b>MC.</b> Consulting or Advisory Role: AstraZeneca, Merck, Astellas, Medivation. <b>CK.</b> Honoraria: Bristol-Myers Squibb, Pfizer. Consulting or Advisory Role: Bristol-Myers Squibb, Pfizer. <b>BIR.</b> Consulting or Advisory Role: Bristol-Myers Squibb. <b>DYCH.</b> Consulting or Advisory Role: Bristol-Myers Squibb, Pfizer, Novartis. <b>JK.</b> No relationship to disclose. <b>MHV.</b> Honoraria: Novartis. Consulting or Advisory Role: GlaxoSmithKline, Exelixis, Natera, Calithera, Pfizer. Research Funding: Bristol-Myers Squibb, Roche/Genentech. Travel, Accommodations, Expenses: Takeda, Novartis. <b>JS.</b> Honoraria: Celgene, Lilly. Consulting or Advisory Role: Celgene, Lilly. Research Funding: Celgene, Sanofi, Roche. <b>EB.</b> Employment: Bristol-Myers Squibb. Stock or Other Ownership: Bristol-Myers Squibb. <b>LY.</b> Employment: Bristol-Myers Squibb, at the time the study was performed. Stock or Other Ownership: Bristol-Myers Squibb, at the time the study was performed. <b>HJH.</b> Consulting or Advisory Role: Bristol-Myers Squibb, Pfizer, Exelixis. Research Funding: Bristol-Myers Squibb. Travel, Accommodations, Expenses: Bristol-Myers Squibb, Pfizer, Exelixis.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.